دورية أكاديمية
أعرض في EDS

Integrins and Actions of Androgen in Breast Cancer.

التفاصيل البيبلوغرافية
العنوان: Integrins and Actions of Androgen in Breast Cancer.
المؤلفون: Tsai CC; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.; Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan., Yang YSH; Joint Biobank, Office of Human Research, Taipei Medical University, Taipei 11031, Taiwan., Chen YF; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan., Huang LY; Department of Pediatrics, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan., Yang YN; Department of Pediatrics, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan.; School of Medicine, I-Shou University, Kaohsiung 82445, Taiwan., Lee SY; Dentistry, Wan-Fang Medical Center, Taipei Medical University, Taipei 11031, Taiwan.; School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan., Wang WL; Department of Life Science, Fu Jen Catholic University, New Taipei City 242, Taiwan., Lee HL; Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 110, Taiwan.; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan., Whang-Peng J; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan., Lin HY; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Traditional Herbal Medicine Research Center of Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.; Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA., Wang K; Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
المصدر: Cells [Cells] 2023 Aug 22; Vol. 12 (17). Date of Electronic Publication: 2023 Aug 22.
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Androgens*/pharmacology , B7-H1 Antigen*, Male ; Humans ; Endothelial Cells ; Integrin alphaVbeta3 ; Cell Transformation, Neoplastic
مستخلص: Androgen has been shown to regulate male physiological activities and cancer proliferation. It is used to antagonize estrogen-induced proliferative effects in breast cancer cells. However, evidence indicates that androgen can stimulate cancer cell growth in estrogen receptor (ER)-positive and ER-negative breast cancer cells via different types of receptors and different mechanisms. Androgen-induced cancer growth and metastasis link with different types of integrins. Integrin αvβ3 is predominantly expressed and activated in cancer cells and rapidly dividing endothelial cells. Programmed death-ligand 1 (PD-L1) also plays a vital role in cancer growth. The part of integrins in action with androgen in cancer cells is not fully mechanically understood. To clarify the interactions between androgen and integrin αvβ3, we carried out molecular modeling to explain the potential interactions of androgen with integrin αvβ3. The androgen-regulated mechanisms on PD-L1 and its effects were also addressed.
References: Horm Cancer. 2013 Dec;4(6):335-42. (PMID: 23943159)
Front Immunol. 2020 Oct 21;11:568931. (PMID: 33193345)
Mol Endocrinol. 2003 May;17(5):870-81. (PMID: 12554777)
J Biomed Sci. 2022 Jun 15;29(1):41. (PMID: 35705962)
Cancer Res. 2023 Feb 3;83(3):456-470. (PMID: 36469363)
Endocrinology. 1997 Apr;138(4):1406-12. (PMID: 9075695)
Cancers (Basel). 2021 Jan 27;13(3):. (PMID: 33513758)
Cancer Biol Med. 2021 Oct 09;:. (PMID: 34623791)
Oncogene. 2005 Jul 7;24(29):4660-71. (PMID: 15897907)
Neoplasia. 2008 Jun;10(6):542-8. (PMID: 18516291)
Cancer Biol Ther. 2015;16(1):52-9. (PMID: 25427201)
Mol Cancer. 2014 Sep 08;13:208. (PMID: 25200184)
Adv Protein Chem Struct Biol. 2019;116:135-170. (PMID: 31036290)
Cancer Lett. 2014 Aug 28;351(1):64-71. (PMID: 24944078)
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006478. (PMID: 22229119)
J Cell Physiol. 2010 Jan;222(1):156-67. (PMID: 19780039)
Physiol Rev. 2021 Jan 1;101(1):319-352. (PMID: 32584192)
Genome Biol. 2007;8(5):215. (PMID: 17543136)
Int J Cancer. 2006 Feb 15;118(4):889-98. (PMID: 16152594)
Mol Med. 2007 Jan-Feb;13(1-2):79-88. (PMID: 17515959)
Int J Mol Sci. 2023 Mar 29;24(7):. (PMID: 37047395)
Cancer Res. 2016 Sep 1;76(17):5163-74. (PMID: 27450452)
J Mol Endocrinol. 2004 Jun;32(3):793-810. (PMID: 15171713)
Histopathology. 2023 Apr;82(5):664-671. (PMID: 36527253)
Exp Cell Res. 2001 Apr 1;264(2):307-14. (PMID: 11262187)
J Extracell Vesicles. 2022 Aug;11(8):e12234. (PMID: 35923105)
Biomed Pharmacother. 2021 Jun;138:111436. (PMID: 33667790)
Oncogene. 2021 Feb;40(6):1043-1063. (PMID: 33420366)
Mol Endocrinol. 2014 Jun;28(6):935-48. (PMID: 24739041)
Cancer Metastasis Rev. 2010 Mar;29(1):207-22. (PMID: 20111892)
EMBO J. 2000 Oct 16;19(20):5406-17. (PMID: 11032808)
PLoS One. 2011 Jan 14;6(1):e15942. (PMID: 21264241)
Mol Med Rep. 2018 Jun;17(6):8203-8211. (PMID: 29658587)
Cell Death Dis. 2020 Jul 6;11(7):506. (PMID: 32632098)
Anticancer Res. 2005 Jan-Feb;25(1A):79-83. (PMID: 15816522)
NPJ Breast Cancer. 2016 Feb 24;2:16002. (PMID: 28721372)
Carcinogenesis. 2021 Feb 11;42(1):38-47. (PMID: 32832992)
FEBS J. 2013 May;280(10):2207-15. (PMID: 23375101)
Endocr Relat Cancer. 2016 Oct;23(10):R485-98. (PMID: 27528625)
PLoS One. 2013 Oct 09;8(10):e76899. (PMID: 24130806)
PLoS One. 2013 Oct 09;8(10):e76513. (PMID: 24130778)
Oncogene. 2008 Aug 28;27(37):5057-68. (PMID: 18504439)
Int J Mol Sci. 2020 Apr 21;21(8):. (PMID: 32326308)
PLoS One. 2021 Jan 22;16(1):e0244985. (PMID: 33481853)
Curr Oncol Rep. 2015 Feb;17(2):4. (PMID: 25665553)
Gland Surg. 2020 Dec;9(6):2106-2115. (PMID: 33447561)
Mol Cancer Ther. 2014 May;13(5):1067-77. (PMID: 24674886)
Int J Endocrinol. 2015;2015:294278. (PMID: 26491440)
Breast Cancer Res. 2020 Jun 9;22(1):61. (PMID: 32517735)
Cancers (Basel). 2022 Jan 12;14(2):. (PMID: 35053528)
BMC Cancer. 2014 Apr 23;14:283. (PMID: 24758408)
Cancer Immunol Res. 2014 Apr;2(4):361-70. (PMID: 24764583)
Cancer Res. 2014 Mar 1;74(5):1598-608. (PMID: 24385215)
Steroids. 2016 Oct;114:41-47. (PMID: 27394959)
PLoS One. 2014 Jan 31;9(1):e86238. (PMID: 24497940)
J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):52-8. (PMID: 16797178)
Oncogene. 2021 Apr;40(15):2667-2681. (PMID: 33692467)
Cell Biochem Biophys. 2010 Sep;58(1):31-44. (PMID: 20652762)
Clin Cancer Res. 2016 Apr 15;22(8):1969-77. (PMID: 26573597)
Cancer Res. 2002 May 1;62(9):2699-707. (PMID: 11980671)
Methods Mol Biol. 2012;757:369-97. (PMID: 21909923)
Cancer Biol Ther. 2022 Dec 31;23(1):173-185. (PMID: 35188070)
J Biol Chem. 2023 Jan;299(1):102725. (PMID: 36410437)
Ann N Y Acad Sci. 2006 Nov;1089:194-200. (PMID: 17261767)
Acta Pharmacol Sin. 2022 Feb;43(2):429-445. (PMID: 33824459)
Mol Cell Endocrinol. 2006 Jul 11;253(1-2):36-43. (PMID: 16723184)
Cell Adh Migr. 2013 May-Jun;7(3):251-61. (PMID: 23563505)
Cell Physiol Biochem. 2007;20(6):977-86. (PMID: 17982280)
Oncol Rep. 2009 Aug;22(2):327-35. (PMID: 19578773)
Cell. 2002 Sep 20;110(6):673-87. (PMID: 12297042)
J Steroid Biochem Mol Biol. 1995 May;52(5):459-67. (PMID: 7748811)
Am J Transl Res. 2020 Apr 15;12(4):1428-1442. (PMID: 32355552)
Sci Rep. 2022 Nov 7;12(1):18879. (PMID: 36344556)
Oncogene. 2020 Jul;39(31):5390-5404. (PMID: 32565538)
Science. 2002 Apr 5;296(5565):151-5. (PMID: 11884718)
Sci Rep. 2019 Mar 14;9(1):4490. (PMID: 30872694)
Breast Cancer Res. 2020 Dec 4;22(1):136. (PMID: 33276802)
PLoS One. 2014 Feb 14;9(2):e88557. (PMID: 24551119)
Genes Dis. 2018 May 12;5(2):77-106. (PMID: 30258937)
Cell Death Dis. 2019 Sep 9;10(9):649. (PMID: 31501409)
PLoS One. 2012;7(8):e41613. (PMID: 22927910)
Oncol Res Treat. 2017;40(5):294-297. (PMID: 28346916)
J Steroid Biochem Mol Biol. 2019 Sep;192:105406. (PMID: 31185279)
J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):182-8. (PMID: 19159686)
Urol Int. 2008;81(3):353-9. (PMID: 18931557)
Cells. 2020 Aug 03;9(8):. (PMID: 32756527)
J Physiol. 2009 Nov 1;587(Pt 21):5019-23. (PMID: 19687123)
Endocrinology. 2000 Sep;141(9):3172-82. (PMID: 10965888)
Nat Commun. 2021 Sep 1;12(1):5209. (PMID: 34471106)
Breast Cancer Res. 2023 Jan 31;25(1):13. (PMID: 36721218)
Nat Med. 2021 Feb;27(2):310-320. (PMID: 33462444)
Am J Clin Pathol. 2003 Nov;120(5):725-31. (PMID: 14608899)
Int J Nanomedicine. 2017 Oct 27;12:7913-7921. (PMID: 29138558)
J Biomed Res. 2011 Jul;25(4):237-45. (PMID: 23554696)
J Biol Chem. 2009 Dec 4;284(49):33966-81. (PMID: 19837659)
Biochem Soc Trans. 2000;28(4):311-39. (PMID: 10961914)
Oncotarget. 2015 Nov 3;6(34):35866-79. (PMID: 26456774)
Breast Cancer Res. 2021 Nov 4;23(1):102. (PMID: 34736512)
J Carcinog. 2011;10:20. (PMID: 21886458)
Elife. 2022 Mar 14;11:. (PMID: 35285795)
RSC Adv. 2019 Feb 15;9(10):5682-5691. (PMID: 35515929)
Cell Death Dis. 2022 Feb 8;13(2):123. (PMID: 35136023)
Front Cell Dev Biol. 2022 Feb 14;10:829788. (PMID: 35237605)
Mol Cancer. 2022 Jun 29;21(1):138. (PMID: 35768871)
J Clin Invest. 1995 Oct;96(4):1815-22. (PMID: 7560073)
BMC Urol. 2008 Apr 23;8:7. (PMID: 18433501)
Mod Pathol. 2010 May;23(5):644-53. (PMID: 20208479)
Breast Cancer Res. 2015 Feb 25;17:28. (PMID: 25849225)
Endocrinology. 2002 Oct;143(10):3897-904. (PMID: 12239101)
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7589-94. (PMID: 15897451)
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. (PMID: 27284266)
J Pathol. 2015 Apr;235(5):760-72. (PMID: 25430721)
J Biol Chem. 2013 Jul 5;288(27):19593-603. (PMID: 23696648)
Oncogene. 2006 Jun 29;25(28):3994-4008. (PMID: 16491124)
Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312. (PMID: 31511835)
J Clin Invest. 2011 Jul;121(7):2750-67. (PMID: 21633166)
فهرسة مساهمة: Keywords: PD-L; androgen; androgen receptor; breast cancer; integrin αvβ3
المشرفين على المادة: 0 (Androgens)
0 (B7-H1 Antigen)
0 (Integrin alphaVbeta3)
تواريخ الأحداث: Date Created: 20230908 Date Completed: 20230911 Latest Revision: 20230911
رمز التحديث: 20230912
مُعرف محوري في PubMed: PMC10486718
DOI: 10.3390/cells12172126
PMID: 37681860
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4409
DOI:10.3390/cells12172126